Baxter International, the world’s biggest maker of blood-disease treatments which is also based in Malta, beat analysts’ expectations yesterday after it posted profits of $569 million for the last three months of 2008, up from $478 million posted in the same period the year before.
“Baxter is not playing defense, but rather investing heavily [in capital improvements and research and development] to fund future growth,” a source quoted by the Chicago Sun-Times says.
This is yet another case where investment in innovation and constant improvement pays off.
Recent Comments